MX339137B - Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal. - Google Patents
Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal.Info
- Publication number
- MX339137B MX339137B MX2014009529A MX2014009529A MX339137B MX 339137 B MX339137 B MX 339137B MX 2014009529 A MX2014009529 A MX 2014009529A MX 2014009529 A MX2014009529 A MX 2014009529A MX 339137 B MX339137 B MX 339137B
- Authority
- MX
- Mexico
- Prior art keywords
- gip
- analogues
- glucose
- modified
- terminal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
La presente invención se refiere a una serie de análogos novedosos de compuestos de polipéptido insulinotrópico dependiente de glucosa, composiciones farmacéuticas que contienen dichos compuestos, y el uso de dichos compuestos como agonistas o antagonistas del receptor GIP para el tratamiento de condiciones mediadas por el receptor GIP, como diabetes mellitus no dependiente de insulina y obesidad.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18818708P | 2008-08-07 | 2008-08-07 | |
US20061208P | 2008-12-02 | 2008-12-02 | |
PCT/US2009/004559 WO2010016944A2 (en) | 2008-08-07 | 2009-08-07 | Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
Publications (1)
Publication Number | Publication Date |
---|---|
MX339137B true MX339137B (es) | 2016-05-13 |
Family
ID=41664130
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014009529A MX339137B (es) | 2008-08-07 | 2009-08-07 | Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal. |
MX2011001032A MX2011001032A (es) | 2008-08-07 | 2009-08-07 | Analogos polipeptidos de insulinotropicos dependientes de glucosa (gip) modificados en n terminal. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011001032A MX2011001032A (es) | 2008-08-07 | 2009-08-07 | Analogos polipeptidos de insulinotropicos dependientes de glucosa (gip) modificados en n terminal. |
Country Status (12)
Country | Link |
---|---|
US (2) | US8999940B2 (es) |
EP (2) | EP2769986A3 (es) |
JP (3) | JP2011530509A (es) |
KR (3) | KR20110043689A (es) |
CN (2) | CN102171243A (es) |
AU (1) | AU2009280021B2 (es) |
BR (1) | BRPI0917580A2 (es) |
CA (1) | CA2733006A1 (es) |
EA (1) | EA020091B1 (es) |
HK (1) | HK1201844A1 (es) |
MX (2) | MX339137B (es) |
WO (1) | WO2010016944A2 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA020005B1 (ru) | 2008-08-07 | 2014-07-30 | Ипсен Фарма С.А.С. | Аналоги глюкозазависимого инсулинотропного полипептида |
AU2009280021B2 (en) * | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
KR101417873B1 (ko) | 2008-08-07 | 2014-07-09 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 |
WO2011018611A1 (en) * | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
FR2994848B1 (fr) | 2012-08-30 | 2014-08-22 | Univ Paris Curie | Traitement de l'arthrose par les hormones incretines ou leurs analogues |
SE536738C2 (sv) | 2012-11-02 | 2014-07-01 | Heatcore Ab | Värmeväxlarplatta för plattvärmeväxlare, plattvärmeväxlare innefattande sådana värmeväxlarplattor och anordning för uppvärmning innefattande plattvärmeväxlaren |
CN115990242A (zh) | 2013-03-01 | 2023-04-21 | 康德生物医疗有限公司 | 预防或治疗巴斯综合征的方法和组合物 |
US10793597B2 (en) | 2013-03-01 | 2020-10-06 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation |
MY172744A (en) * | 2013-05-28 | 2019-12-11 | Takeda Pharmaceuticals Co | Peptide compound |
WO2014209905A2 (en) * | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods and compositions for detecting and diagnosing diseases and conditions |
EP3530671A3 (en) | 2014-09-05 | 2019-11-13 | University of Copenhagen | Gip peptide analogues |
JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
CN105061566A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 拟胰岛素多肽及其应用 |
CA3009650A1 (en) | 2015-12-23 | 2017-06-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
CN110461861A (zh) * | 2016-11-09 | 2019-11-15 | 南洋理工大学 | 人参肽和人参肽类似肽的制备和利用 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
PL3630806T3 (pl) | 2017-05-31 | 2024-05-13 | The University Of Copenhagen | Analogi peptydów gip o długotrwałym działaniu |
ES2961384T3 (es) | 2018-05-04 | 2024-03-11 | Novo Nordisk As | Derivados de GIP y usos de los mismos |
CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
IL296219A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Weekly doses of gip receptor agonist peptides and their uses |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562175A (en) * | 1984-02-03 | 1985-12-31 | Ding Chang | Synthetic peptides |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
US7091183B1 (en) | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
WO1999038536A1 (en) | 1998-01-29 | 1999-08-05 | Poly-Med Inc. | Absorbable microparticles |
WO2000004916A1 (en) | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
AR020650A1 (es) | 1998-08-10 | 2002-05-22 | Poly Med Inc | Polimeros fosforilados y conjugados de los mismos |
AU1603500A (en) | 1998-11-02 | 2000-05-22 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Lactone bearing absorbable polymers |
CA2778047A1 (en) | 1998-12-07 | 2000-06-15 | Ipsen Pharma S.A.S | Analogues of glp-1 |
US6903186B1 (en) * | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US6921748B1 (en) | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
GB0404124D0 (en) * | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
EP1392484B1 (en) * | 2001-04-06 | 2013-06-12 | California Institute Of Technology | High throughput screening of crystalization of materials |
TWI284539B (en) * | 2001-07-30 | 2007-08-01 | Epix Pharm Inc | A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide |
US20030232761A1 (en) * | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
RU2339398C2 (ru) * | 2002-10-22 | 2008-11-27 | Уэйрейта Фармасьютиклз, Инк. | Лечение диабета |
EP2080521A1 (en) | 2002-10-22 | 2009-07-22 | Waratah Pharmaceuticals, Inc. | Gastrin compositions and formulations, and methods of use and preparation |
WO2005047334A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
US7897566B2 (en) * | 2003-12-16 | 2011-03-01 | Ipsen Pharma S.A.S. | Analogues of GLP-1 |
SG159551A1 (en) * | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
EP1937716A2 (en) | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US20090170762A1 (en) * | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
JPWO2007049695A1 (ja) | 2005-10-26 | 2009-04-30 | 中外製薬株式会社 | 凝集性glp−1アナログおよび徐放性医薬組成物 |
EP2057188B1 (en) * | 2006-08-17 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
AU2009280021B2 (en) * | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
-
2009
- 2009-08-07 AU AU2009280021A patent/AU2009280021B2/en not_active Ceased
- 2009-08-07 EP EP13195741.7A patent/EP2769986A3/en not_active Withdrawn
- 2009-08-07 JP JP2011522071A patent/JP2011530509A/ja active Pending
- 2009-08-07 KR KR1020117003756A patent/KR20110043689A/ko active Application Filing
- 2009-08-07 CN CN2009801394417A patent/CN102171243A/zh active Pending
- 2009-08-07 BR BRPI0917580A patent/BRPI0917580A2/pt active Search and Examination
- 2009-08-07 WO PCT/US2009/004559 patent/WO2010016944A2/en active Application Filing
- 2009-08-07 KR KR1020137031534A patent/KR20130133103A/ko active Application Filing
- 2009-08-07 MX MX2014009529A patent/MX339137B/es unknown
- 2009-08-07 CN CN201410406367.3A patent/CN104231070B/zh not_active Expired - Fee Related
- 2009-08-07 CA CA2733006A patent/CA2733006A1/en not_active Abandoned
- 2009-08-07 MX MX2011001032A patent/MX2011001032A/es not_active Application Discontinuation
- 2009-08-07 KR KR1020157011870A patent/KR101593158B1/ko not_active IP Right Cessation
- 2009-08-07 EP EP09805295A patent/EP2318433A4/en not_active Withdrawn
- 2009-08-07 US US13/057,966 patent/US8999940B2/en not_active Expired - Fee Related
- 2009-08-07 EA EA201170305A patent/EA020091B1/ru not_active IP Right Cessation
-
2011
- 2011-10-17 HK HK15101504.0A patent/HK1201844A1/xx unknown
-
2013
- 2013-10-02 JP JP2013207223A patent/JP5986550B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-05 US US14/639,210 patent/US20150175665A1/en not_active Abandoned
-
2016
- 2016-02-19 JP JP2016029639A patent/JP2016175892A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA020091B1 (ru) | 2014-08-29 |
KR20130133103A (ko) | 2013-12-05 |
JP5986550B2 (ja) | 2016-09-06 |
HK1201844A1 (en) | 2015-09-11 |
KR101593158B1 (ko) | 2016-02-12 |
KR20150056668A (ko) | 2015-05-26 |
JP2014051501A (ja) | 2014-03-20 |
BRPI0917580A2 (pt) | 2016-10-11 |
EP2318433A2 (en) | 2011-05-11 |
US20110136725A1 (en) | 2011-06-09 |
CN104231070B (zh) | 2017-09-01 |
EP2769986A2 (en) | 2014-08-27 |
EP2318433A4 (en) | 2012-08-08 |
EP2769986A3 (en) | 2014-11-26 |
CA2733006A1 (en) | 2010-02-11 |
KR20110043689A (ko) | 2011-04-27 |
JP2016175892A (ja) | 2016-10-06 |
US8999940B2 (en) | 2015-04-07 |
WO2010016944A3 (en) | 2010-04-29 |
EA201170305A1 (ru) | 2011-10-31 |
AU2009280021A1 (en) | 2010-02-11 |
JP2011530509A (ja) | 2011-12-22 |
US20150175665A1 (en) | 2015-06-25 |
WO2010016944A2 (en) | 2010-02-11 |
AU2009280021B2 (en) | 2012-10-04 |
CN102171243A (zh) | 2011-08-31 |
MX2011001032A (es) | 2011-08-12 |
CN104231070A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX339137B (es) | Analogos de polipeptidos insulinotropicos dependientes de glucosa (gip) modificados en n terminal. | |
WO2010016940A3 (en) | Analogues of glucose-dependent insulinotropic polypeptide | |
WO2010016935A3 (en) | Truncated analogues of glucose-dependent insulinotropic polypeptide | |
WO2010016938A3 (en) | Glucose-dependent insulinotropic polypeptide analogues | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
PH12020551742A1 (en) | Gip derivatives and uses thereof | |
MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
HK1158192A1 (en) | Piperidine gpcr agonists | |
GB0812642D0 (en) | Compounds | |
CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
JOP20220024A1 (ar) | مركبات مساعدة لـ gipr | |
MX2013006304A (es) | Analogos de glucagon que exhiben actividad del receptor gip. | |
HK1135703A1 (en) | Piperidine gpcr agonists | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
CL2007002197A1 (es) | Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl | |
EA201001801A1 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения | |
CL2007003766A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, artritis, obesidad, insuficiencia cardiaca, enfermedades neurodegenerativas, cardiovasculares, dislipid | |
WO2007003962A3 (en) | Gpcr agonists | |
WO2007003961A3 (en) | Gpcr agonists | |
CL2008000018A1 (es) | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci | |
ZA200808687B (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
CL2007001530A1 (es) | Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes. | |
MX2010003440A (es) | Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo. | |
MX2010003442A (es) | Compuesto inhibidor de fosforilasa de glicogeno y composicion farmaceutica del mismo. | |
GB0602639D0 (en) | Organic compounds |